“The medical preparation of the invention produces most unexpected and beneficial results, by for example alleviating fears and anxieties which may have been present in the patient”
1/12
The patents claimed medical preparations of:
(1) ibogaine, iboga alkaloid extract, or total extract; plus
(2) amphetamine, MDA, TMA, tetrahydronapthylamine, or naphazoline
“The best results have been obtained with” MDA
The combination “forms an excellent medicine"
2/12
The ibogaine “has the effect of considerably clarifying the mind of the sick person, giving him a kind of extra-lucid vision of his ‘ego.’ It likewise excites the memory centre of the brain thus revealing memories which may go back to a period before the age of 4…”
3/12
“The amphetamine derivative associated with the iboga extract, on the other hand, permits the emotional character necessary as complement to the stimulation of the mind and imagination as produced by the iboga to be restored to the patient.”
4/12
“A toxicological study of the product has showed that secondary effects, e.g. vomiting & vertigo, are almost non-existent & that the medicine showed absolutely no danger as regards life or the biological balance of the invalid. The toxicity of this association is thus nil.”
5/12
“In view of the extreme efficiency of the medicine, it seems pointless to visualise treatments of long duration.
The medicine, when used in psychotherapy, is in fact outstanding…at no time should the practician need to exceed 5 psychotherapy sessions…”
6/12
“The spheres of application are immense.
Numerous clinical tests show that the medicine can be used in all diseases of psychosomatic character or of which the psychosomatic origin can be visualised.”
More than 50 cases were studied in psychiatry with 50 mental patients…”
7/12
Case 1:
“A woman aged 35 years was treated for symptoms corresponding to an anxiety neurosis”
5 preparatory sessions, 3 drug sessions, “one or two interviews”
“Conclusion: No re-appearance of fears and a considerable improvement in the characterological difficulties."
8/12
Case 2:
“A woman aged 23 years attended bc of conflicts w her husband. She envisaged the possibility of divorce…before taking action, she decided to find out to what point her actual refusal to her husband could be the consequence of personal psychological difficulties.”
9/12
Case 3:
“A man aged 30 years was affected by sexual troubles, homosexual tendency & sexual unsatisfaction in his conjugal life.
One treatment session which comprised a dosage of total extract of the iboga combined w MDA produced a substantial improvement to his problem.”
What happens when two companies’ patents both cover the same drug?
Reunion Neuroscience’s lead RE104 = isoprocin glutarate, a prodrug of 4-OH-DiPT
Reunion $REUN has a granted patent claiming it
Today, Mindset Pharma $MSET received a notice of allowance on claims to it too
1/7
Field Trip $FTRP (the original applicant) obtained its patent on RE104 (then FT-104) after first w/drawing it from issuance to ensure examiner reviewed Mindset’s apps
Mindset’s were filed first, but only published after Field Trip’s app was allowed
New patent granted—“Delivery System for Ayahuasca-Like Substances”
Claims DMT vapes, 5-MeO-DMT vapes, & 2C-B vapes
These claims can be immediately enforced
1/6
The patent claims:
“A device for the delivery of a substance comprising:
a chamber comprising at least one vaporizable formulation wherein the vaporizable formulation comprises the substance and wherein the substance comprises one or more of”
DMT, 5-MeO-DMT, or 2C-B
2/6
The application was first filed as a provisional in July 2020
Did DMT vape pens exist in the prior art before the priority date?
This @doubleblindmag article was first published on Feb. 5, 2020: